[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CE

What happened: Roche reported third quarter sales growth of +7% at constant exchange rates and +8% in CHF, with Group sales up +6% (CER) and +1% in CHF in the first nine months of 2026. Key numbers: Group sales CHF 46.5 billion in the first nine months. Pharmaceuticals Division CHF 36.2 billion, +7% CER. Diagnostics Division CHF 10.3 billion, +4% CER. Why it matters: Roche confirmed its full-year outlook and cited high demand for innovative medicines and diagnostics as the driver. The company said it aims to bring up to 20 new medicines to patients by 2030.

Roche reported third quarter sales growth of +7% at constant exchange rates and +8% in CHF, with Group sales up +6% (CER) and +1% in CHF in the first nine months of 2026.

Roche confirmed its full-year outlook and cited high demand for innovative medicines and diagnostics as the driver. The company said it aims to bring up to 20 new medicines to patients by 2030.